CURE

FDA Fully Approves Braftovi Combo for BRAF V600E Metastatic Colorectal Cancer

The U.S. Food and Drug Administration (FDA) has granted traditional approval to Braftovi (encorafenib) for adult patients ...

Engineered liver scaffolds reveal how colorectal cancer hides and goes dormant

Colorectal liver metastases (CRLM), cancer that has spread from the colon or rectum to the liver, have a deadly reputation. Due to its pervasive spread, typical cancer treatments like chemotherapy and ...
Healio

Encorafenib combination secures FDA approval for metastatic colorectal cancer

The FDA has approved the first combination, targeted regimen for previously untreated BRAF V600E mutation-positive metastatic colorectal cancer.Encorafenib (Braftovi, Pfizer) plus cetuximab (Erbitux, ...

Clues in the bloodstream reveal the role androgen receptor alterations play in metastatic prostate cancer

A new study using serial liquid biopsies to track how metastatic prostate cancer evolves under treatment pressure showed that ...
Business Wire

U.S. FDA Grants Full Approval to Pfizer’s BRAFTOVI Combination Regimen in First-Line Metastatic Colorectal Cancer

Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has granted full approval to BRAFTOVI® (encorafenib) in combination ...
ascopubs.org

Investigating Racial and Ethnic Disparities Along the Care Cascade for Older Adults Newly Diagnosed With Metastatic Cancer

Reply to: “Rethinking Treatment Priorities in Estrogen Receptor–Low Breast Cancer” and “CDK4/6 Inhibitors in Estrogen Receptor–Low Breast Cancer” In the article that accompanies this editorial, Lin et ...
Novartis

New real‑world data reinforce earlier use of Pluvicto™ before chemotherapy in metastatic castration-resistant prostate cancer

In the real-world, Pluvicto™ showed 13.5 months median PFS in chemo-naïve patients with PSMA-positive mCRPC; Real‑world evidence showed Pluvicto achieved longer PFS when init ...